EP3672639

COMBINATION PRODUCT OF A BCL-2 INHIBITOR AND IBRUTINIB FOR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER

  • :
    EP einkaleyfi: Þýðing ekki lögð inn
  • :
    30.7.2019
  • :
    23.2.2022
  • :
    19844315.2
  • :
    29.7.2039
  • :
    COMBINATION PRODUCT OF A BCL-2 INHIBITOR AND IBRUTINIB FOR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER

30.7.2019
23.2.2022
  • :
    Ascentage Pharma (Suzhou) Co., Ltd.
  • :
    Unit 701, Building B7, 218 Xinghu Street Suzhou Industrial Park, Suzhou, Jiangsu 215000, CN
  • :
    YANG, Dajun
  • :
    Suzhou, Jiangsu 215000, CN
  • :
    ZHAI, Yifan
  • :
    Suzhou, Jiangsu 215000, CN
  • :
    FANG, Douglas Dong
  • :
    Suzhou, Jiangsu 215000, CN
  • :
    WANG, Guangfeng
  • :
    Suzhou, Jiangsu 215000, CN
  • :
    ZHAI, Guoqin
  • :
    Suzhou, Jiangsu 215000, CN
  • :
    201810867251
  • :
    31.7.2018
  • :
    CN
  • :
    CN2019098252
  • :
    30.7.2019
  • :
    A61K 31/519, A61K 31/496, A61K 31/635, A61K 31/662, A61K 45/06, A61K 9/00, A61K 9/08, A61K 47/10, A61K 47/20, A61P 29/00, A61P 35/00, A61P 37/06